We are live on ! Find out more
AGN

Allergan plc
AGN

Delisted

AGN was delisted on the 8th of May, 2020.

1,107 hedge funds and large institutions have $79B invested in Allergan plc in 2016 Q2 according to their latest regulatory filings, with 169 funds opening new positions, 500 increasing their positions, 363 reducing their positions, and 172 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 500 | Existing positions reduced: 363

5% more call options, than puts

Call options by funds: $4.83B | Put options by funds: $4.61B

2% less first-time investments, than exits

New positions opened: 169 | Existing positions closed: 172

1% less funds holding

Funds holding: 1,1191,107 (-12)

15% less capital invested

Capital invested by funds: $92.6B → $79B (-$13.6B)

26% less funds holding in top 10

Funds holding in top 10: 155115 (-40)

Holders
1,107
Holders Change
-12
Holders Change %
-1.07%
% of All Funds
29.54%
Holding in Top 10
115
Holding in Top 10 Change
-40
Holding in Top 10 Change %
-25.81%
% of All Funds
3.07%
New
169
Increased
500
Reduced
363
Closed
172
Calls
$4.83B
Puts
$4.61B
Net Calls
+$225M
Net Calls Change
+$2.19B
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
126
Bluefin Capital Management
New York
$103M +$102M +443,994 New
Canada Life
127
Canada Life
Manitoba, Canada
$99M +$14.5M +62,924 +17%
MVIP
128
Mar Vista Investment Partners
California
$98M +$23.6M +102,467 +32%
CIC
129
Chilton Investment Company
Connecticut
$96.2M -$3.49M -15,127 -4%
GCM
130
Gruss Capital Management
New York
$95.9M +$95.7M +415,000 New
Axa
131
Axa
France
$95.8M +$28.3M +122,774 +42%
ETC
132
Evercore Trust Company
New York
$93.7M -$809K -3,507 -0.9%
D.E. Shaw & Co
133
D.E. Shaw & Co
New York
$92.9M -$435M -1,888,467 -82%
SEI Investments
134
SEI Investments
Pennsylvania
$92.8M -$959K -4,158 -1%
HCM
135
Highfields Capital Management
Massachusetts
$92.4M +$92.2M +400,000 New
ESG
136
Emerging Sovereign Group
New York
$92M +$19.2M +83,340 +26%
Two Sigma Advisers
137
Two Sigma Advisers
New York
$90.7M -$70.8M -307,101 -44%
WA
138
WestEnd Advisors
North Carolina
$90.3M +$11.2M +48,425 +14%
Caisse de Depot et Placement du Quebec (CDPQ)
139
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
$89.5M +$76.5M +331,700 +597%
Alkeon Capital Management
140
Alkeon Capital Management
New York
$89.3M +$8.13M +35,270 +11%
State of Wisconsin Investment Board
141
State of Wisconsin Investment Board
Wisconsin
$88.5M -$35.4M -153,580 -29%
Citadel Advisors
142
Citadel Advisors
Florida
$86.3M +$77.4M +335,910 +897%
CRM
143
Cramer Rosenthal McGlynn
Connecticut
$85.1M +$34.6M +150,269 +69%
MP
144
Manikay Partners
New York
$84.4M -$11.5M -49,750 -12%
SCM
145
Steadfast Capital Management
New York
$84.1M +$19.6M +85,145 +31%
Group One Trading
146
Group One Trading
Illinois
$83.9M +$46.5M +201,790 +125%
Korea Investment Corp
147
Korea Investment Corp
South Korea
$83M +$28.6M +124,100 +53%
HCM
148
Hoplite Capital Management
New York
$83M +$13.7M +59,475 +20%
RJA
149
Raymond James & Associates
Florida
$82.7M +$13.6M +58,982 +20%
MDSL
150
M.D. Sass LLC
New York
$81.8M +$20.2M +87,771 +33%

AGN Hedge Fund Activity: Q2 2016 in Review

1,107 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Allergan plc (AGN) for Q2 2016, worth a combined $79B — down 15% from $92.6B a quarter earlier.

Sellers outnumbered buyers: 172 funds closed out of AGN and 169 opened new positions — a net loss of 3 holders — while 363 trimmed existing stakes and 500 added.

The largest buyer was Icahn Carl, opening a new position worth an estimated $784M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.03B.

  • 1,107 institutional investors held Allergan plc (AGN) as of Q2 2016, down from 1,119 in Q1 2016.
  • Funds reported $79B of Allergan plc stock for Q2 2016, down 15% quarter-over-quarter.
  • 169 funds opened new Allergan plc positions in Q2 2016 and 172 closed out, a net change of -3 holders.
  • The largest Allergan plc buyer in Q2 2016 was Icahn Carl, an estimated $784M added.
  • The largest Allergan plc seller in Q2 2016 was T. Rowe Price Associates, an estimated $1.03B sold.

Based on aggregated 13F filings for Q2 2016.